Liang Chen

Liang Chen

Auto-generated profile, based on publicly available information

Liang Chen

Center for Inflammatory Bowel Disease Research and Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, No. 301, Yanchang Zhong Road, Jingan District, Shanghai 200072, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMingming Sun
Mingming Sun
WWWei Wu
Wei Wu
LCLiang Chen
Liang Chen
WYWenjing Yang
Wenjing Yang
XHXiangsheng Huang
Xiangsheng Huang
YCYingzi Cong
Yingzi Cong
T-cells are crucial in maintanence of intestinal homeostasis, however, it is still unclear how microbiota metabolites regulate T-effector cells. Here we show gut microbiota-derived short-chain fatty acids (SCFAs) promote microbiota antigen-specific Th1 cell IL-10 production, mediated by G-protein coupled receptors 43 (GPR43). Microbiota antigen-specific Gpr43−/− CBir1 transgenic (Tg) Th1 cells, specific for microbiota antigen CBir1 flagellin, induce more severe colitis compared with wide type (WT) CBir1 Tg Th1 cells in Rag−/− recipient mice. Treatment with SCFAs limits colitis induction by promoting IL-10 production, and administration of anti-IL-10R antibody promotes colitis development. Mechanistically, SCFAs activate Th1 cell STAT3 and mTOR, and consequently upregulate transcription factor B lymphocyte-induced maturation protein 1 (Blimp-1), which mediates SCFA-induction of IL-10. SCFA-treated Blimp1−/− Th1 cells produce less IL-10 and induce more severe colitis compared to SCFA-treated WT Th1 cells. Our studies, thus, provide insight into how microbiota metabolites regulate Th1 cell functions to maintain intestinal homeostasis.

27 March 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
LCLiang Chen
Liang Chen
MSMingming Sun
Mingming Sun
WWWei Wu
Wei Wu
WYWenjing Yang
Wenjing Yang
XHXiangsheng Huang
Xiangsheng Huang
YCYingzi Cong
Yingzi Cong
How the gut microbiota regulates intestinal homeostasis is not completely clear. Gut microbiota metabolite short-chain fatty acids (SCFAs) have been reported to regulate T-cell differentiation. However, the mechanisms underlying SCFA regulation of T-cell differentiation and function remain to be investigated. CBir1, an immunodominant microbiota antigen, transgenic T cells were treated with butyrate under various T-cell polarization conditions to investigate butyrate regulation of T-cell differentiation and the mechanism involved. Transfer of butyrate-treated CBir T cells into Rag1-/- mice was performed to study the in vivo role of such T cells in inducing colitis. Although butyrate promoted Th1 cell development by promoting IFN-γ and T-bet expression, it inhibited Th17 cell development by suppressing IL-17, Rorα, and Rorγt expression. Interestingly, butyrate upregulated IL-10 production in T cells both under Th1 and Th17 cell conditions. Furthermore, butyrate induced T-cell B-lymphocyte-induced maturation protein 1 (Blimp1) expression, and deficiency of Blimp1 in T cells impaired the butyrate upregulation of IL-10 production, indicating that butyrate promotes T-cell IL-10 production at least partially through Blimp1. Rag1-/- mice transferred with butyrate-treated T cells demonstrated less severe colitis, compared with transfer of untreated T cells, and administration of anti-IL-10R antibody exacerbated colitis development in Rag-/- mice that had received butyrate-treated T cells. Mechanistically, the effects of butyrate on the development of Th1 cells was through inhibition of histone deacetylase but was independent of GPR43. These data indicate that butyrate controls the capacity of T cells in the induction of colitis by differentially regulating Th1 and Th17 cell differentiation and promoting IL-10 production, providing insights into butyrate as a potential therapeutic for the treatment of inflammatory bowel disease.

1 January 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MSMingming Sun
Mingming Sun
CHChong He
Chong He
LCLiang Chen
Liang Chen
WYWenjing Yang
Wenjing Yang
WWWei Wu
Wei Wu
YCYingzi Cong
Yingzi Cong
The role of retinoid-related orphan receptor γ t (RORγt) in Th17 cell differentiation has been well established; however, how it regulates other T cell lineages is still not clearly understood. In this study, we report that in mice, while promoting Th17 cell differentiation, RORγt inhibited IL-10 production by T cells, thereby preserving the pathogenicity of Th17 cells. Treatment with RORγt-specific inhibitor suppressed Th17 cell signature cytokines, but promoted IL-10 production. RORγt inhibitor–treated Th17 cells induce less severe colitis compared with control Th17 cells. Mechanistically, the RORγt inhibitor induced T cell expression of Blimp-1 (encoded by Prdm1). Prdm1−/− T cells produced significantly fewer IL-10 when treated with RORγt inhibitor compared with wild-type T cells. Furthermore, RORγt inhibitor–treated Prdm1−/− Th17 cells induce more severe colitis compared with RORγt inhibitor–treated wild-type Th17 cells. Collectively, our studies reveal a novel mechanism by which RORγt drives and maintains pathogenic Th17 cell development by inhibiting IL-10 production.


7 May 2026 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
XLXinglan Li
Xinglan Li
XWXudong Wu
Xudong Wu
DKDengfeng Kang
Dengfeng Kang
LFLeilei Fang
Leilei Fang
CLChangqin Liu
Changqin Liu
LCLiang Chen
Liang Chen
Background: Anti-tumor necrosis factor alpha (anti-TNFα) agents assume a significant role in the management of Crohn’s disease (CD). Exclusive enteral nutrition (EEN) is as effective as corticosteroids for inducing remission in children with active CD, but less effective in adults. Few studies have compared the relative effectiveness of these strategies in achieving endoscopic improvement and symptom relief. Objectives: We aimed to compare the efficacy of EEN, infliximab (IFX), and combination therapy in adult patients with CD. Design: Retrospective cohort study. Methods: Between March 2021 and June 2024, 270 adult patients with active CD were recruited and received EEN, IFX, or combination treatment for 14 weeks. Propensity-score (PS) matching was conducted to balance the baseline characteristics across the three groups. The fecal 16S rRNA sequencing and metabolomics analyses were applied to further analyze the underlying mechanism involved in combination and monotherapy. Results: Of the 270 reviewed patients, a total of 146 PS-matched adult CD patients who received EEN ( n = 29), IFX ( n = 56), and combination therapy ( n = 61), respectively, were analyzed. The combination therapy of EEN plus IFX demonstrated greater improvement in endoscopic response at week 14 compared to both the EEN group ( p = 0.021) and the IFX group ( p = 0.032), but not in endoscopic remission. Combination therapy also exhibited a significantly higher clinical response rate compared with EEN ( p = 0.027) and IFX ( p = 0.038) monotherapy, but no significant difference in clinical remission. Furthermore, compared with IFX monotherapy, combination therapy increased the IFX trough level at week 14 ( p < 0.001). Fecal 16S rRNA sequencing revealed that combination therapy successfully restored the abundance of Bacteroidetes and related genera. Targeted metabolomics further confirmed a significant increase in short-chain fatty acids (SCFA) and key metabolites (e.g., indolelactic acid) in fecal samples 14 weeks after combination therapy. Conclusion: Combination therapy is more effective than EEN or IFX monotherapy for short-term endoscopic and clinical response. Mechanistically, combination therapy reshapes the gut microbiota, restores levels of SCFAs, and increases key protective fecal metabolites, offering a promising strategy for the management of CD.